Why fully human κλ bodies
Whenever antibodies are engineered to differ from their natural counterpart either by using non-human (e.g. murine) sequences or a different format compared to natural IgG, the risk of neutralizing anti-drug antibodies (ADA) arises. These are produced by the body as part of a physiological response against any “foreign” proteins. Exactly this mechanism has prevented the successful use of therapeutic antibodies for more than a decade. Taking advantage of the unique features of human antibody light chains, our partner LightChain Bioscience – NovImmune SA has developed a highly competitive and advantageous antibody platform.
Their κλ bodies consist of two identical heavy chains and two different light chains: one kappa (κ) and one lambda (λ). The resulting bispecific antibodies fully retain the sequence and architecture of human antibodies. By being truly human, the risk of inducing immunogenicity and loss of exposure is minimized. Antibodies in this format are ideally suited for therapeutic application in both benign and malignant diseases. In addition, the κλ format facilitates production/purification.
